Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review.

PMID:
23074314
2.

Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Yang H, Zhang C, Zhou Q, Wang Y, Chen L.

PLoS One. 2015 Jan 9;10(1):e0116769. doi: 10.1371/journal.pone.0116769. eCollection 2015. Review.

3.

Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.

Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, Aduroja OA, Amde M, Groszek JJ, Wei P, Taylor ME, Tolwani AJ, Fissell WH.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1377-83. doi: 10.2215/CJN.10260915. Epub 2016 May 19.

4.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group.

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
5.

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Winstead EM, Ratliff PD, Hickson RP, Mueller JE, Judd WR.

Int J Clin Pharm. 2016 Oct;38(5):1087-93. doi: 10.1007/s11096-016-0334-1. Epub 2016 Jun 22.

PMID:
27333796
6.

Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.

Mah GT, Mabasa VH, Chow I, Ensom MH.

Ann Pharmacother. 2012 Feb;46(2):265-75. doi: 10.1345/aph.1Q378. Epub 2012 Jan 24. Review.

PMID:
22274145
7.

Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Cotrina-Luque J, Gil-Navarro MV, Acosta-García H, Alfaro-Lara ER, Luque-Márquez R, Beltrán-García M, Bautista-Paloma FJ.

Int J Clin Pharm. 2016 Feb;38(1):70-9.

PMID:
26474861
8.

Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?

Attivi D, Gibaud S.

Ann Pharm Fr. 2014 May;72(3):146-51. doi: 10.1016/j.pharma.2013.12.006. Epub 2014 Jan 20. Review.

PMID:
24780830
9.

Is extended or continuous infusion of carbapenems the obvious solution to improve clinical outcomes and reduce mortality?

Frippiat F, Vercheval C, Lambermont B, Damas P.

Clin Infect Dis. 2013 Jul;57(2):324-5. doi: 10.1093/cid/cit205. Epub 2013 Apr 1. No abstract available.

PMID:
23547169
10.

Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.

McCormick H, Tomaka N, Baggett S, Heierman T, LaFosse J, Gilbert S, Imhof K.

Am J Health Syst Pharm. 2015 Jun 1;72(11 Suppl 1):S25-30. doi: 10.2146/sp150007.

PMID:
25991590
11.

Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.

Yusuf E, Spapen H, Piérard D.

J Crit Care. 2014 Dec;29(6):1089-95. doi: 10.1016/j.jcrc.2014.07.033. Epub 2014 Aug 7. Review.

PMID:
25179412
12.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
13.

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.

Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R.

Pharmacotherapy. 2002 Apr;22(4):471-83.

PMID:
11939682
14.

Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.

Yang H, Cui X, Ma Z, Liu L.

J Pharm Pharm Sci. 2016 Apr-Jun;19(2):274-89. doi: 10.18433/jpps.v19i2.27517. Review.

15.

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.

Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.

Int J Antimicrob Agents. 2005 Jan;25(1):62-7.

PMID:
15620828
16.

Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.

D'Agostino C, Rhodes NJ, Skoglund E, Roberts JA, Scheetz MH.

J Infect Chemother. 2015 Oct;21(10):742-6. doi: 10.1016/j.jiac.2015.05.010. Epub 2015 Jun 9.

PMID:
26143049
17.

Pharmacokinetic evaluation of piperacillin-tazobactam.

Hayashi Y, Roberts JA, Paterson DL, Lipman J.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31. doi: 10.1517/17425255.2010.506187. Review.

PMID:
20636224
18.

Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.

Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Pogue JM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3743-50. doi: 10.1128/AAC.03011-15. Print 2016 Jun.

19.

Rationale and evidence for extended infusion of piperacillin-tazobactam.

Kaufman SE, Donnell RW, Hickey WS.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1521-6. doi: 10.2146/ajhp100694. Review.

PMID:
21817083
20.

Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.

Lee GC, Liou H, Yee R, Quan CF, Neldner K.

Clin Ther. 2012 Dec;34(12):2297-300. doi: 10.1016/j.clinthera.2012.11.005. Epub 2012 Nov 27.

PMID:
23195962

Supplemental Content

Support Center